

Research use only. Not for use in diagnostic procedures.

PhotoScreen® Ion Channel Cell Line

human TRPA1 Ion Channel Cell Line

Product No.: AX-004-PCL

Lot No.: 2293079

Material Provided

Cells: 2 x 1 mL frozen aliquot (AX-004-PCLV)

Format: ~2.5 x 10⁶ cells /mL in freezing medium

Product Information

Cellular Background: HEK-293

Cell Line Development: An expression vector containing the coding sequence of the human

Transient Receptor Potential cation channel subfamily A member 1 (TRPA1) ion channel under the control of the CMV promoter was transfected in HEK-293 cells stably expressing mitochondrially targeted Photina®. Resistant clones were obtained by limiting dilution and compared for their response to a reference agonist

using the PhotoScreen® assay.

DNA Sequence: Identical to coding sequence of GenBank NM_007332.1

Corresponding Protein Sequence: Identical to GenBank 075762.1

Receptor expression level (B_{max}) Not determined for this cell line.

Shipping Conditions: Shipped on dry ice. Please ensure dry ice is still present in the

package upon receipt or contact customer support.

Storage Conditions: Store in liquid nitrogen (vapor phase) immediately upon receipt.



Quality Control

The EC₅₀ value for a reference agonist was determined in a PhotoScreen® assay performed with adherent cells on a LumiLux® instrument. A mycoplasma test was performed using MycoAlert® Mycoplasma (Lonza) detection kit. We certify that these results meet our quality release criteria.

Trans-Cinnamaldehyde (EC₅₀): N/A

Stability: Cells were kept in continuous culture for 20 passages (~ 60 days) and showed

no decrease in functional response in the PhotoScreen® assay (EC50, Emax).

Mycoplasma: This cell line tested negative for Mycoplasma.

Recommended Cell Culture Conditions

Complete Medium: MEM/EBSS, 10% fetal bovine serum (FBS), 400 ug/mL G418 sulfate.

Freezing Medium: MEM/EBSS, 10% fetal bovine serum (FBS) with 10% DMSO, without selection agents.

Thawing Cells: Using appropriate personal protective equipment, place the frozen aliquot in a 37° C water bath (do not submerge) and agitate until its content is thawed completely. Immediately remove from water bath, spray aliquot with 70° ethanol and wipe excess with a towel. Under aseptic conditions using a pipette, transfer content to 10° mL complete medium and centrifuge (150° x g, 5° min). Resuspend cell pellet in 10° mL of complete medium and transfer to an appropriate culture flask (see recommended seeding density below). Cells are cultured as a monolayer at 37° C in a humidified atmosphere with 5° CO₂.

Recommended Seeding Density: 41,000 - 45,000 cells/cm²

Cell Culture Protocol: Typically, for regular cell culture maintenance, these cells are grown to 80% confluence and trypsinized (0.05% trypsin / 0.5 mM EDTA in calcium and magnesium free HBSS). Under these conditions, cell passages should be carried out every 3-5 days.



Typical Product Data - PhotoScreen® Assay

Please refer to User Manual for culture conditions and detailed assay protocols.

Agonist	pEC ₅₀	TOP Agonist (RLU)	% of Digitonin Response
<i>trans-</i> cinnamaldehyde	3.6	166 000	80%
AITC	4.3	166 000	-
BITC	4.3	173 000	-




Figure 1. PhotoScreen® Agonist Dose Response. Coelenterazine-loaded cells (20,000 cells) were dispensed into the wells of a black, clear bottom 384-well plate containing the agonist dilutions. Signal was measured from 10 to 40 s following cell addition on the LumiLux® Cellular Screening Platform.




Figure 2. PhotoScreen® Antagonist Dose Response. Coelenterazine-loaded cells (20,000 cells) were dispensed into the wells of a black, clear bottom 384-well plate containing the antagonist dilutions. After 10 min, the agonist (EC_{80} final concentration) was added and signal measured from 50 to 80 s following agonist addition on the LumiLux® Cellular Screening Platform.



References

- 1. Bovolenta S, Foti M, Lohmer S, Corazza S. (2007) Development of a Ca²⁺-activated photoprotein, Photina[®], and its application to high-throughput screening. J Biomol Screen. 12: 694-704.
- 2. Button D, Brownstein M. (1993) Aequorin-expressing mammalian cell lines used to report Ca²⁺ mobilization. Cell Calcium. 14: 663-671.
- 3. Sheu YA, Kricka LJ, Pritchett DB. (1993) Measurement of intracellular calcium using bioluminescent aequorin expressed in human cells. Anal Biochem. 209: 343-347.
- 4. Stables J, Green A, Marshall F, Fraser N, Knight E, Sautel M, Milligan G, Lee M, Rees S. (1997) A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal Biochem. 252: 115-126.



Materials and Instrumentation

		SUPPLIER	CATALOG #	
CELL C	CULTURE			
•	DMEM/F-12	Invitrogen	11320	
•	RPMI	Invitrogen	11875-135	
•	EMEM	Lonza	BE06-174G	
•	Sodium Pyruvate	Invitrogen	11360	
•	PEN-STREP	Lonza	DE17-602E	
•	Geneticin/G418	Invitrogen	11811-031	
•	Puromycin	Sigma-Aldrich	P7255	
•	PBS	Lonza	BE17-515Q	
•				
PHOTOSCREEN® ASSAY				
•	DMEM/F-12	Invitrogen	11039	
•	BSA, protease free	Sigma-Aldrich	A3059	
•	Native Coelenterazine	Promega	S2001	
•	Digitonin	Sigma-Aldrich	37006	
•	Trans-cinnamaldehyde	Sigma-Aldrich	239 968	

CLIDDLIED

CATALOC #

This product is not for resale or distribution except by authorized distributors. The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



940 Winter Street

940 Winter Street Waltham, MA 02451 USA (800) 762-4000 www.revvity.com For a complete listing of our global offices, visit www.revvity.com Copyright ©2023, Revvity, Inc. All rights reserved.